Head-to-head · WeighScore
Renlo Health vs SexyMD
By GLP-1 ScorecardUpdated
Score comparison
Renlo Health has the higher recorded score — 79.7/100 to 60.3/100.
Renlo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs whose headline is the actual monthly rate, with the prescribing physician and the dispensing pharmacy both named.
Before you choose
Before comparing the headline prices, the Renlo Health review and the SexyMD review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Renlo Health vs ShapeIn Rx and Science & Co vs SexyMD compare each of them with another graded program, and the list of alternatives to Renlo Health ranks the programs closest to Renlo Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Renlo Health | SexyMD |
|---|---|---|
| WeighScore | 79.7/100 | 60.3/100 |
| Grade | C+ | C |
| Site position | #40 | #354 |
| Semaglutide | $149/mo at every dose (shown against $299) | $149/mo (4-week plan; $99/mo on 48-week plan; compounded) |
| Tirzepatide | $199/mo at every dose (shown against $399) | $199/mo (4-week plan; $129/mo on 48-week plan; compounded) |
| Coverage | Not publicly listed | 47 states (all except Arkansas, Mississippi and New Jersey) |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
- A genuine all-in line: medication, injection supplies, provider evaluation, ongoing care, expedited shipping and unlimited care-team messaging, with no membership or consultation fees
- Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
- Same price at every dose with a price-lock badge
- A four-month money-back guarantee, and cancel anytime with no fee
What to consider
- A struck-through $399 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
- That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
- A comparison table headed "Most GLP-1 providers" quotes $270, $365 and $445 by dose while naming no provider and citing no source
- A site-wide $50 code means the advertised figure is not the first amount charged
- No lab protocol is published, and there is no oral or brand route
Strengths
- Publishes an exact exclusion list — all states except Arkansas, Mississippi and New Jersey — rather than a nationwide claim
- States both compounding classes in the Terms, so the class question is answered even though the pharmacy is not named
- Names the prescribing entity and the professional corporation behind it
- Sells two microdose products with their own published price tables rather than only as a discount tier
What to consider
- Every headline price is the 48-week commitment rate: $99 against a four-week figure of $149, and $129 against $199, with an asterisk that resolves to no footnote
- The same footer, on every page, says both that the service is available in all 50 states and that it is available in all states except three
- The two microdose products publish identical prices for their 4-, 8- and 12-week plans, in the same table format that carries real tiers elsewhere
- The microdose page contradicts itself on dosing frequency inside a single page
- Three unsourced and mutually inconsistent social-proof figures appear across the homepage, the footer and the product pages
- The checkout claims two patient counts for a single day that together exceed the total the site's own badge claims
- No pharmacy is named, and what the price includes is never itemized on any product page
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.